Rice Hall James & Associates’s Viridian Therapeutics VRDN Stock Holding History

Rice Hall James & Associates’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.6M	Buy	898,611 +14,079	+2%	+$418K	0.98%	31
2025 Q4	$27.5M	Buy	884,532 +32,869	+4%	+$901K	1.52%	16
2025 Q3	$18.4M	Buy	851,663 +336,040	+65%	+$6.06M	1%	30
2025 Q2	$7.21M	Buy	515,623 +152,730	+42%	+$2.07M	0.39%	66
2025 Q1	$4.89M	Buy	362,893 +309,518	+580%	+$5.27M	0.29%	77
2024 Q4	$1.02M	Buy	+53,375	New	+$1.16M	0.06%	204

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rice Hall James & Associates's VRDN Position: Q1 2026 in Review

Rice Hall James & Associates increased its Viridian Therapeutics (VRDN) stake by 1.6% in Q1 2026, buying an estimated $418K and bringing the position to 898,611 shares worth $17.6M. The position accounts for 0.98% of the portfolio, ranked #31.

Rice Hall James & Associates first reported a position in VRDN in Q4 2024 and has held it in 6 quarters since. The position peaked at $27.5M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Rice Hall James & Associates held 898,611 shares of Viridian Therapeutics worth $17.6M as of Q1 2026.
Rice Hall James & Associates bought 14,079 Viridian Therapeutics shares in Q1 2026, an estimated $418K.
Viridian Therapeutics made up 0.98% of Rice Hall James & Associates's portfolio in Q1 2026, its #31 holding.
Rice Hall James & Associates first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 6 quarters since.
Rice Hall James & Associates's Viridian Therapeutics position peaked at $27.5M in Q4 2025.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.